Multiple Myeloma
From the Journals
Cardiovascular complications most common with carfilzomib in relapsed myeloma
For patients taking carfilzomib-based therapy, the most common complications were heart failure, followed by grade 3 or 4 hypertension.
From the Journals
TP53 double hit predicts aggressive myeloma
Researchers said the findings point to the usefulness of clonal competition assays to reveal the impact of genomic lesions in tumors and better...
Opinion
Potential improvements in convenience, tolerability of hematologic treatment
Dr. Alan P. Lyss dissects the practice changing elements of the COLUMBA trial in multiple myeloma and the ASCEND trial in CLL.
Conference Coverage
SC daratumumab deemed feasible for every multiple myeloma patient
CHICAGO – In the COLUMBA trial, subcutaneous daratumumab proved noninferior to intravenous daratumumab in overall response rate and maximum trough...
From the Journals
Recombinant vaccine cut herpes zoster rate in immunocompromised patients
In a randomized clinical trial of 1,846 adults who had undergone autologous HSCT, herpes zoster cases were seen in 49 and 136 individuals in the...
Latest News
FDA approves Xpovio for relapsed/refractory multiple myeloma
The oral therapy was approved for patients who have received at least four prior therapies and whose disease is resistant to several other forms...
News
Daratumumab wins new indication for newly diagnosed myeloma patients
Daratumumab plus lenalidomide and dexamethasone (DRd) is now approved for newly diagnosed myeloma patients who are ineligible for autologous stem...
Conference Coverage
Triplet offers longest PFS yet seen in relapsed/refractory myeloma
CHICAGO – Patients who received isatuximab plus pomalidomide and dexamethasone had a median progression-free survival of 11.53 months.
Conference Coverage
Four-drug combo bests triplet in newly diagnosed myeloma
CHICAGO – Results with daratumumab plus bortezomib, thalidomide, and dexamethasone are the “best ever reported in the setting of stem cell...
From the Journals
Daratumumab regimen shows benefit in transplant-ineligible myeloma
The alkylator-free regimen of daratumumab plus lenalidomide and dexamethasone appears safe and effective for patients who are ineligible for stem...
Conference Coverage
Lenalidomide may reduce risk of progression from SMM to MM
At 3 years, the rate of progression-free survival was 91% in patients with smoldering multiple myeloma who were randomized to lenalidomide and 66...